Bazedoxifene is a third bearing careful estrogen receptor modulator (SERM), developed by Pfizer afterward the achievement of their takeover of Wyeth Pharmaceuticals. In backward 2013, Pfizer accustomed approval for bazedoxifene as allotment of the aggregate biologic DUAVEE in the blockage (not treatment) of postmenopausal osteoporosis. It is accustomed in the European Union (marketed in Italy and Spain) and Japan, and is in the backward phases of analysis by the United States' Food and Biologic Administration (FDA).
Bazedoxifene belongs to a chic of compounds accepted as careful estrogen receptor modulators (SERMs). Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending aloft the corpuscle and tissue blazon and ambition genes. Bazedoxifene decreases cartilage absorption and reduces biochemical markers of cartilage about-face to the premenopausal range. These furnishings on cartilage remodelling advance to an access in cartilage mineral body (BMD), which in about-face contributes to a abridgement in the accident of fractures. Bazedoxifene functions primarily as an oestrogen-receptor adversary in uterine and breast tissues.